Arthur Cohen and Joseph Healey‘s Healthcor Management has added Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) to its equity portfolio. The fund revealed holding 1.5 million shares of the company, the stake being equal to 5.39% of the outstanding stock.
Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)s is a small cap healthcare company engaged in developing biotechnology products related to oxygen delivery to tissue. Its stock has gained around 24% since the beginning of the year. For the last quarter of 2013, the company reported a net loss of $0.86 per diluted share, narrowing the loss from $1.45 per share reported for the previous quarter. For 2014, analysts expect the company to deliver a net loss of -$0.87 per share.
Aside from Healthcor, another investor, that has started a stake in Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) recently, is Hal Mintz‘ Sabby Management. Sabby reported, earlier this month, holding more than 1.96 million shares of the company, which represent 7.43% of the outstanding stock. Ellington, managed by Mike Vranos, has also added the company to its equity portfolio during the last quarter of 2013, although it holds a less significant stake, which contains just 34,200 shares.
Earlier this year, Healthcor Management, reported boosting its position in another small-cap healthcare company, CareView Communications Inc (OTCBB:CRVW). In two filings, Healthcor disclosed raising its holding to 39.13 million shares, and then to 55.63 million, which represent 28.6% of the outstanding stock.
Healthcare stocks amass the largest portion of Healthcor’s $1.65 billion equity portfolio. The fund holds the largest position in Allscripts Healthcare Solutions Inc (NASDAQ:MDRX): 10.00 million shares, worth $154.6 million. McKesson Corporation (NYSE:MCK) is the next largest holding, which has been raised by 250% over the quarter to 600,000 shares; followed by Cubist Pharmaceuticals Inc (NASDAQ:CBST), in which the fund owns 1.4 million shares.